CFI finds no likelihood of confusion between RNAiFect and RNActive

    March 2010

    In CureVac GmbH v OHIM (Case T80/08), the CFI dismissed an action brought by CureVac GmbH against the First Board of Appeal's rejection of CureVac's opposition to Qiagen GmbH's CTM application for RNAiFect. The action was dismissed as it was held that there was no likelihood of confusion between CureVac's earlier trade mark, RNActive and RNAiFect.